Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,291 active trials259 approved drugs3,814 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04459065 | Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery | recruiting | Phase 1 / Phase 2 | 36 | University of SaskatchewanOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT04897490 | RWE of 1st Line Treatment With ATO/ATRA for Adult APL | recruiting | — | 50 | Grupo Argentino de Tratamiento de la Leucemia AgudaOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT04938804 | Non-risk Based Lang Cancer Screening With a One-off LDCT | recruiting | N/A | 11,000 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05127148 | RWE of Pediatric-like Protocol for AYA Patients With Ph-negative ALL | recruiting | — | 100 | Grupo Argentino de Tratamiento de la Leucemia AgudaOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05140746 | Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer | recruiting | N/A | 40 | Ruijin HospitalOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05246345 | Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia(RAVEN) | recruiting | — | 50 | University Hospital, Clermont-FerrandOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06196190 | Prognostic Value of Conization and Negative HPV After Conization in AIS and Early Stage Cervical Cancer | recruiting | — | 200 | Rambam Health Care CampusOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06196255 | Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05675813 | Genotype-guided Treatment in Newly Diagnosed PTCL(THEORY) | recruiting | Phase 1 / Phase 2 | 264 | Ruijin HospitalOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT05833763 | A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.(GOlDiLOX) | recruiting | Phase 2 | 42 | Australasian Leukaemia and Lymphoma GroupOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT06194708 | Reasons for Non-reversal of Temporary Stomas After Surgeries of Mid-low Rectal Cancer （NORESTO Study） | recruiting | — | 235 | Peking Union Medical College HospitalOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT04716686 | Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma | recruiting | Phase 2 | 83 | Shandong UniversityOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT05964569 | Feasibility of Individualized, Model-guided Optimization of Proton Beam Treatment Planning in Patients With Low Grade Glioma(INDIGO) | recruiting | Phase 2 | 120 | University Hospital HeidelbergOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06190639 | A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC | recruiting | Phase 2 | 31 | Zhejiang Cancer HospitalOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04831983 | ABlative Radiotherapy (for) Unfavorable Prostate Tumors(ABRUPT) | recruiting | — | 30 | University of Milano BicoccaOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06088030 | Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer | recruiting | Phase 2 | 50 | Yang LiOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06165900 | Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC | recruiting | Phase 2 | 136 | Shengjing HospitalOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06188650 | The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study | recruiting | N/A | 30 | Ningbo Medical Center Lihuili HospitalOTHER_GOV | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06188676 | Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL | recruiting | Phase 3 | 100 | National Research Center for Hematology, RussiaNETWORK | 1 | Jan 3, 2024 | clinicaltrials |
| NCT05839392 | Novel Approaches to Target MECOM/EVI1 in AML | recruiting | N/A | 24 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT06185569 | FREDO-ODX Study: FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guided Therapy(FREDO-ODX-23) | recruiting | — | 4,500 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04050228 | Use of Quantitative Ultrasound to Guide Adaptive Chemotherapy Among Women With Breast Cancer | recruiting | N/A | 240 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT05446545 | Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian Cancer(EOC) | recruiting | — | 139 | Fudan UniversityOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT06180174 | Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma | recruiting | Phase 1 | 24 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Dec 28, 2023 | clinicaltrials |
| NCT05173272 | Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer | recruiting | Phase 3 | 286 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT05189054 | Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors | recruiting | — | 40 | Peking University Third HospitalOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT05349552 | Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites | recruiting | — | 120 | Peking University Third HospitalOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT05833594 | Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma | recruiting | — | 70 | Anhui Provincial HospitalOTHER_GOV | 1 | Dec 26, 2023 | clinicaltrials |
| NCT06061146 | Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC(TCRTOE) | recruiting | Phase 2 | 136 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT06177015 | Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC | recruiting | Phase 3 | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT04894370 | Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma(SPARTANA) | recruiting | Phase 2 | 34 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT05245487 | Danish Elder Lymphoma Patient Hematopoietic Investigation(DELPHI) | recruiting | — | 300 | Rigshospitalet, DenmarkOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT05991102 | Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With TAS-102 (Lonsurf) and Bevacizumab in Refractory Metastatic Colorectal Cancer(Live-RF) | recruiting | N/A | 12 | Charite University, Berlin, GermanyOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT06168786 | Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC | recruiting | Phase 2 | 40 | Huazhong University of Science and TechnologyOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT06001086 | A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer | recruiting | Phase 2 | 70 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT06155318 | 68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours | recruiting | — | 300 | IRCCS San RaffaeleOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT06176729 | Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients | recruiting | Phase 2 | 30 | Yan Zhang, MDOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT06177925 | A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC | recruiting | Phase 2 | 62 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT05427383 | KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy | recruiting | Phase 2 / Phase 3 | 286 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05302284 | A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma | recruiting | Phase 3 | 452 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT06173986 | Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer | recruiting | Phase 1 / Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT05029791 | Variations of Immune Infiltrate and Cell Plasticity Markers in Treated Metastatic Melanoma Patients(COLEMAN) | recruiting | N/A | 100 | Hospices Civils de LyonOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT05620290 | MRI-Guided Focused Ultrasound Radiosensitization for Patients With Malignant Melanoma and Non Melanoma Skin Cancer | recruiting | Phase 1 | 20 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT05689619 | SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)(SILMET) | recruiting | N/A | 70 | A.O.U. Città della Salute e della ScienzaOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT06092957 | Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy | recruiting | Phase 3 | 504 | Sun Yat-sen UniversityOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT04050423 | Investigation of Ultrasound Imaging and Spectroscopy for Characterizing Breast Masses | recruiting | — | 1,200 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT04134780 | Ultrasound Imaging and Spectroscopy as Early Indicators of Locally-Advanced Breast Cancer Response | recruiting | — | 150 | Sunnybrook Health Sciences CentreOTHER | 2 | Dec 14, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Jan 9, 2024source: clinicaltrials